Biocon Q1 Core Operations Shine

  Published 1 year ago

Biocon’s Q1 FY26 saw core EBITDA grow 11% YoY, with strong biosimilars and CRDMO growth offsetting one-time gains.

  • Biosimilars revenue jumped 18% YoY to Rs 2,458 crore, fueled by strong demand and new product launches globally.
  • CRDMO business grew 11% in revenue and 19% in EBITDA, driven by pilot programs converting into long-term contracts.
  • Operating revenue rose 15% YoY to Rs 3,942 crore, reflecting broad-based growth across biosimilars, generics, and research services.

You might like these

Maruti Suzuki Exports Jump 32% in July

Colgate India Falls on Weak Q1

Perplexity Eyes Smartphone Browser Push

Tilaknagar Soars on Imperial Blue Deal

Rupee Declines Amid Dollar Demand & Data

Nestlé India Profit Falls 12% in Q1

Castrol Wins ₹4,131 Cr Tax Case

News that matters the most ⚡